SBFM · Sunshine Biopharma Inc. · Executive Compensation
Market Cap
$3.27M
Shares
3.88M
Volume · Oct 5
2.09M
Avg daily vol (3M)
544.98K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Mr. Camille Sebaaly | Chief Financial Officer | $695,000 |
| Dr. Steve N. Slilaty | Chief Executive Officer and Director | $560,000 |
| Dr. Abderrazzak Merzouki | Chief Operating Officer and Director | $260,000 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Camille Sebaaly | Chief Financial Officer | $930,000 |
| Mr. Camille Sebaaly | Chief Financial Officer | $930,000 |
| Dr. Abderrazzak Merzouki | Chief Operating Officer and Director | $485,000 |
| Dr. Steve N. Slilaty | Chief Executive Officer and Director | $370,000 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Dr. Steve N. Slilaty | Chief Executive Officer and Director | $462,380 |
| Dr. Abderrazzak Merzouki | Chief Operating Officer and Director | $415,927 |
| Camille Sebaaly | Chief Financial Officer | $346,000 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Dr. Abderrazzak Merzouki | chief operating officer | Resigned | 2026-02-05 |
| Michel Roy | Chief Commercial Officer | Appointed | 2025-01-15 |
| Malek Chamoun | Chief Development Officer | Appointed | 2024-01-30 |
| Camille Sebaaly | Chief Financial Officer and Secretary | Appointed | 2024-01-30 |
| Marc Beaudoin | Chief Operating Officer | Appointed | 2024-01-30 |
| Dr. Abderrazzak Merzouki | Chief Science Officer | Appointed | 2024-01-30 |
| Dr. Steve N. Slilaty | President and Chief Executive Officer | Appointed | 2024-01-30 |